New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool

NEXT STORY
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
PREV STORY
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Molecular Diagnostics Market Analysis to 2022 – Molecular Diagnostics Take the Center Stage in COVID-19 Testing

author_avatar
NASDAQ Market News

PositiveID Subsidiary Chief Science Officer Delivers Co-Authored Report to U.S. Department of Defense on Agroterrorism Threat

“Defending Against Agroterrorism: Modeling Pathogen Dispersion Pathways” applies onsite pathogen detection expertise of the ...

author_avatar
NASDAQ Market News

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting

Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a ...

author_avatar
NASDAQ Market News